Dillard’S, Inc.
$8.99B- Market cap
- $10.26B
- Debt
- +-$402.20M
- Cash
- −$861.46M
Capital structure 104% equity / -4% debt · EV / Revenue 1.37x · EV / EBITDA 12.93x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: DDS stock price at discount vs BMRN $656.69 current versus $1.35K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at DDS's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DDS FY 2026 (ended Jan 31, 2026) · BMRN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 104% equity / -4% debt · EV / Revenue 1.37x · EV / EBITDA 12.93x
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
BMRN carries the larger enterprise value at $12.07B against $8.99B; DDS trades on the lower EV / Revenue multiple (1.37x vs 3.75x); DDS on the lower EV / EBITDA (12.93x vs 21.37x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DILLARD’S, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.23x
0.08x
Net debt / EBITDA
Leverage against operating earnings
-1.82x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$861.46M
$1.31B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Macy's, Inc.
DDS vs M
KOHLS Corp
DDS vs KSS
TJX COMPANIES INC /DE/
DDS vs TJX
NORDSTROM INC
DDS vs JWN
VERTEX PHARMACEUTICALS INC / MA
DDS vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
DDS vs ALNY
Sarepta Therapeutics, Inc.
DDS vs SRPT
REGENXBIO Inc.
DDS vs RGNX
IONIS PHARMACEUTICALS INC
DDS vs IONS
PTC THERAPEUTICS, INC.
DDS vs PTCT
-$402.20M
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.